CN101366968A - Compound magnesium sulfate wet-dressing agent and preparation method thereof - Google Patents
Compound magnesium sulfate wet-dressing agent and preparation method thereof Download PDFInfo
- Publication number
- CN101366968A CN101366968A CNA2008101517861A CN200810151786A CN101366968A CN 101366968 A CN101366968 A CN 101366968A CN A2008101517861 A CNA2008101517861 A CN A2008101517861A CN 200810151786 A CN200810151786 A CN 200810151786A CN 101366968 A CN101366968 A CN 101366968A
- Authority
- CN
- China
- Prior art keywords
- magnesium sulfate
- compound magnesium
- dressing agent
- wet
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 title claims abstract description 128
- 229910052943 magnesium sulfate Inorganic materials 0.000 title claims abstract description 85
- 235000019341 magnesium sulphate Nutrition 0.000 title claims abstract description 85
- -1 Compound magnesium sulfate Chemical class 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 title claims description 38
- 208000002193 Pain Diseases 0.000 claims abstract description 57
- 230000036407 pain Effects 0.000 claims abstract description 54
- 230000001954 sterilising effect Effects 0.000 claims abstract description 25
- 230000008961 swelling Effects 0.000 claims abstract description 25
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960004194 lidocaine Drugs 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000008215 water for injection Substances 0.000 claims abstract description 21
- 206010030113 Oedema Diseases 0.000 claims abstract description 19
- 206010033675 panniculitis Diseases 0.000 claims abstract description 16
- 208000001297 phlebitis Diseases 0.000 claims abstract description 16
- 210000004304 subcutaneous tissue Anatomy 0.000 claims abstract description 16
- 239000004033 plastic Substances 0.000 claims abstract description 11
- 229920003023 plastic Polymers 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims description 25
- 238000004659 sterilization and disinfection Methods 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims description 15
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 15
- 238000004140 cleaning Methods 0.000 claims description 11
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 7
- YTYBKUMQBAPTAX-UHFFFAOYSA-N carbonic acid;2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide Chemical compound OC(O)=O.OC(O)=O.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C YTYBKUMQBAPTAX-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000004745 nonwoven fabric Substances 0.000 claims description 6
- 239000004576 sand Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 abstract description 9
- 238000012856 packing Methods 0.000 abstract description 8
- 239000000243 solution Substances 0.000 abstract description 8
- 210000003462 vein Anatomy 0.000 abstract description 7
- 238000002791 soaking Methods 0.000 abstract description 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 201000000297 Erysipelas Diseases 0.000 description 6
- 206010015866 Extravasation Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000036251 extravasation Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000021317 sensory perception Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000032912 Local swelling Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZGBSOTLWHZQNLH-UHFFFAOYSA-N [Mg].S(O)(O)(=O)=O Chemical compound [Mg].S(O)(O)(=O)=O ZGBSOTLWHZQNLH-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound magnesium sulphate wet packing and a preparation method thereof. The compound magnesium sulphate wet packing consists of 20 to 50 percent of magnesium sulphate, 0.1 to 4 percent of lidocaine, the balance being surplus water for injection and medical carrier. The preparation method comprises the steps of soaking the medical carrier in compound magnesium sulphate solution for thirty to sixty minutes after being made into sheets and being disinfected and sterilized, sterilizing the medical carrier with steam for thirty to forty-five minutes, and then putting the medical carrier into a plastic bag to be sealed and packed to prepare the compound magnesium sulphate wet packing. The compound magnesium sulphate wet packing can effectively prevent chemotherapy phlebitis; and the clinical trials show that through the compound magnesium sulphate wet packing, the effective rate of caring and treating swelling and pain caused by edema on local subcutaneous tissue when chemotherapy drugs are instilled in the vein of the patient is over 90 percent, thereby reducing the pain of the patient effectively and improving the quality of life of the patient.
Description
Technical field
The invention belongs to field of medical technology, relate to the Wet-dressing agent that the swelling pain that edema produces appears in the prophylactic treatment local subcutaneous tissue, saying so more specifically a kind ofly has antiinflammatory and removes the swollen compound magnesium sulfate wet-dressing agent of effect and preparation method thereof that relieves the pain.
Background technology
Clinically in the Chang Yong venous transfusion because negligent supervision easily causes non-aggressive medicine or corrosive medicine or solution to enter surrounding tissue causes and ooze out and exosmose, particularly chemotherapeutics is because the oral drugs kind is few, weak curative effect, so vein is the main path that medicine is taken in.But because many chemotherapeutics are chemistry and alkaloid formulations, mechanical stimulus such as repeated multiple times puncture and high concentration medicine can cause the administration vein to local strong stimulation and adjacent tissue is rubescent, swelling, pain sclerosis of blood vessels etc. in addition.There is statistics report 70% above inpatient need accept intravenous injection treatment, the phlebitis that nearly 80% occurrence degree does not wait among these patients.Phlebitis takes place as 87% patient behind the intravenous injection nvelbine.In case chemotherapeutics extravasation takes place gently then cause the local organization swelling pain, heavy then cause the skin ischemic necrosis, even dysfunction or physical disabilities, financial burden and body and mind misery brought to patient, also cause unnecessary medical tangle, even the patient stays lifelong deformity.
Drug extravasation, mainly by following mechanism body is caused damage: the stimulation to blood vessel causes that tube wall chemical inflammation causes vascular permeability to increase, organize inflammatory exudation, medicine oozes out the infiltration subcutaneous tissue in addition, causes impaired vein skin to form edema on every side.The strong acid of some chemotherapeutics, highly basic or hypertonicity stimulation simultaneously can induce the proliferative cell maturation arrest also can cause local organization toxicity, causes endothelial injury.In the compounding pharmaceutical process,, also can make little microgranule intravasation, stimulate the injured blood vessel inwall, produce tissue edema, form inflammation not according to rule of operation, dosing environmental pollution.Combine with histiocytic DNA behind the drug extravasation, be embedded in the DNA chain after oozing out as the anthracene nucleus class, chronic, the serious tissue reaction, the necrosis that cause, the chain reaction of the cytophagy non-viable non-apoptotic cell of normal presence make that healing is very slow; Suppress the generation of inflammatory cell simultaneously, cause the local necrosis protracted course of disease; Cause fibroblastic impaired, the tissue repair difficulty.
The clinical symptoms of drug extravasation mainly contains: 1 often shows as along the blood vessel traveling in infusion process and burns sample pain or local swelling.2 exosmose the injection site local occur red, swollen, hot, bitterly, inflammatory reaction, as handle untimely or do not add to handle and seriously big blister occurs and reach and bunch steep a rash, local purpura ulcer, necrosis appear subsequently.3 purple erythema are hard, burn sample pain, and subcutaneous tissue is got involved, and limitation of activity.4 by the medicine irritation subcutaneous tissue, tissue damaged, and the end of exciting nerve causes radiated pain slightly and adds up neck, the enlargement of axillary lymph knot, septicemia etc.5 ulcer outwards spread necrosis of subcutaneous tissue gradually by the center, and obviously there is epidermal hyperplasia or the like symptom at the edge.Being used for the treatment of at present local subcutaneous tissue swelling pain method commonly used clinically has: in case take place should stop using this venous transfusion immediately after the phlebitis, raise limbs, braking is had a rest, and if any chemotherapeutics extravasation, mainly contains and adopts physics ice cube cold compress to embrocate method, to reduce the activeness of chemotherapeutics, as ooze out morely, then can carry out puncture suction, to reduce local drug concentration to the part, the treatment chemotherapeutic phlebitis is based on local application.But in most cases adopt local external application for curing.Topical remedy's external application for curing chemotherapeutic phlebitis, have easy and simple to handle, the painless advantage of waiting bitterly for, the inventor has also applied for sterilized magnesium sulfate dressing preparation (application number: 200710087101.7) mainly be made of Wet-dressing agent magnesium sulfate solution and medical carrier and move towards the edema generation appears in soak with the subcutaneous tissue that reduces the patient on the vein of injection swelling pain along vein in 2007.03.21.But said method analgesic onset time is slow, and the patient often needs several days ability of continuous soak to eliminate subcutaneous edema, can not satisfy the clinical pain relieving needs of intravenous drip patient such as chemotherapy, phlebitis, erysipelas.
Summary of the invention
But along with deepening continuously of research, the inventor further finds in experiment: magnesium sulfate dressing organizes congestion and edema effective for alleviating, magnesium sulfate dressing is to reach the analgesic effect by eliminating edema, and combined with lidocaine is used can reach the analgesic effect at short notice.Its method is: with the sulfated compound magnesium solution of 20%-50% magnesium sulfate and 0.1%～4% lignocaine and surplus water for injection composition, has beyond thought synergism, to skin zero damage, penetrance and reparation property are strong, can effectively alleviate the stimulation of medicine, improve the toleration of vascular endothelial cell to the ischemia hypoxia, can prevent phlebitic generation, than the stimulation of using magnesium sulfate dressing can alleviate medicine fast and significantly separately, produce the detumescence analgesic effect that obviously is better than the folk prescription magnesium sulfate dressing in the part.Result of the test shows: this compound magnesium sulfate wet-dressing can effective percutaneous infiltration and absorption make its effect more direct, rapider, nervimuscular conduction also capable of blocking, thereby make the peripheral vessels smooth muscle loosening, vasodilation, the blood circulation of local skin promotes to exosmose, thereby alleviate inflammatory reactions such as redness, burning pain, have rapid-action, the characteristics that action time is short.The patient who is particularly suitable for intravenous drips such as chemotherapy, erysipelas, phlebitis uses.
Therefore, an object of the present invention is to provide and be used for the prophylactic treatment local subcutaneous tissue and the compound magnesium sulfate wet-dressing agent that edema produces swelling pain occurs.
Another object of the present invention provides compound magnesium sulfate wet-dressing agent causes pain or local swelling and prevention chemotherapeutic phlebitis aspect in application, particularly chemotherapeutics extravasation aspect the prophylactic treatment local subcutaneous tissue swelling pain application.
Technical scheme of the present invention is as follows:
A kind of compound magnesium sulfate wet-dressing agent is characterized in that, it is to be 20%-50% magnesium sulfate by percetage by weight; Percetage by weight is 0.1%～4% lignocaine and surplus water for injection and medical carrier composition.
Preferably sulfuric acid magnesium percetage by weight of the present invention is 25%-45%; The lignocaine percetage by weight is 1%～3%.The magnesium sulfate percetage by weight that is more preferably is 33%-45%; The lignocaine percetage by weight is 1%～2%.
Compound magnesium sulfate wet-dressing agent of the present invention, lignocaine wherein are lidocaine hydrochloride or lidocaine carbonate.
Medical carrier of the present invention is medical materials such as high-hydroscopicity napkin, non-woven fabrics, gauze or medical dressing sheet.
The preparation method of compound magnesium sulfate wet-dressing agent of the present invention, the following step of its process:
(1) 200g～500g magnesium sulfate is dissolved with an amount of water for injection, standby;
(2) 1g～40g benefit card is dissolved with an amount of water for injection, standby;
(3) will be 1., 2. behind the mixing, water for injection adds to 1000ml, filters with the sand rod, the control pH value is 5～7, medicinal liquid check magnesium sulfate, the qualified back of lignocaine content are standby;
(4) under the working condition of 10,000 grades of cleanings, will be through medical carrier such as high-hydroscopicity napkin, non-woven fabrics or the gauze of sterilization treatment, put into container as carrier, add the medicinal liquid (3) that is up to the standards and soak 30～60min, pack into and seal through in the high pressure resistant pyritous plastic bag of sterilization treatment.
(5) adopt 100 ℃ of steam sterilization 30～45min, make the compound magnesium sulfate wet-dressing sheet.
Preparation method of the present invention is as follows:
(1) get appropriate containers, 200g, 250g, 330g, 450g, 500g magnesium sulfate are added an amount of water for injection dissolving as requested, standby;
(2) get appropriate containers in addition, 5g, 10g, 20g, 30g, 40g lignocaine are added the proper amount of water for injection dissolving as requested, standby,
(3) will be 1., 2. behind the mixing, filter with the sand rod.Medicinal liquid through check wherein magnesium sulfate content and lignocaine content should be up to specification, pH value should be controlled at 5～7, medicinal liquid is standby through after the assay was approved.
(4) under the working condition of 10,000 grades of cleanings, will put into container as carrier through high-hydroscopicity napkin, non-woven fabrics, gauze or the medical dressing of tailoring slabbing of sterilization treatment, add the medicinal liquid that is up to the standards and soak 30min, pack into and seal through in the high pressure resistant pyritous plastic bag of sterilization treatment.Put into the sterilization cabinet then, adopt 100 ℃ of steam sterilization 30min, promptly can be made into.And according to " Chinese Pharmacopoeia 2005 editions " two appendix sterility test methods, testing should be up to specification.
In a particularly preferred example of the present invention, by 500g magnesium sulfate; 5.0g lignocaine; Proper amount of water for injection; Form with hospital gauze.
In another particularly preferred example of the present invention, by 330g magnesium sulfate; The lignocaine of 20g; Proper amount of water for injection; Form with hospital gauze.
In another particularly preferred example of the present invention, by 450g magnesium sulfate; The lignocaine of 10g; Proper amount of water for injection; Form with hospital gauze.
The using method of compound magnesium sulfate wet-dressing agent of the present invention is that the sulfated compound Wet-dressing agent is spread on the swelling pain position, and uses plastic protective film for plastics, all wraps up, and only need stick 1-3 time every day, each 30～60min.During use the compound magnesium sulfate wet-dressing agent sealing bags is taken apart, taken out the wetted high-hydroscopicity napkin of sulfated compound magnesium solution, gauze or medical dressing sheet, can use, also can be used for hot compress or cold compress.In wrapper or packaging bag, also can be provided with sign and operation instruction, can make the patient be well understood to using method, solve the problem of carrying and use inconvenience and infection.
Why the inventor selects the main component of magnesium sulfate as reducing swelling and alleviating pain, be because magnesium sulfate can the antagonism calcium ion, usually magnesium sulfate being used as calcium ion antagonist uses, and calcium ion is to participate in smooth muscle contraction, so magnesium sulfate can the vasodilator smooth muscle since edema be because interstitial fluid too much due to, its tissue is pressed higher, when smooth muscle relaxation, too much interstitial fluid can be along pressure current blood back pipe, and edema will alleviate.
Lignocaine of the present invention comprises: lidocaine hydrochloride or lidocaine carbonate commonly used.Lignocaine is a kind of good local skin anesthetis and efficient Percutaneous absorption enhancer, this medicine stable chemical performance of while, penetration power is strong, onset time is short, the disperse scope is wide, to organizing nonirritant, therefore have significantly press down pain effect and magnesium sulfate associating soak can effective percutaneous infiltration and absorption make its effect more direct, rapider, nervimuscular conduction also capable of blocking, thereby make the peripheral vessels smooth muscle loosening, vasodilation promotes to exosmose the blood circulation of local skin, thereby alleviates inflammatory reactions such as redness, burning pain.Lidocaine carbonate is compared with lidocaine hydrochloride, onset is very fast, and is of flaccid muscles also better, and surface anesthetic effect is 4 times of lidocaine hydrochloride, infiltration anesthesia and spinal anesthesia act as 2 times of lidocaine hydrochloride, and conduction block act as 6 times of lidocaine hydrochloride; Toxicity and lidocaine hydrochloride do not have apparent person's property difference.
The magnesium sulfate that contains variable concentrations that compound magnesium sulfate wet-dressing agent of the present invention adopted, mainly be different with the reason that produces swelling, determine the content of the magnesium sulfate dressing preparation of the various variable concentrations of use at the degree of the intravenous injection medicinal liquid difference of using, swelling.Wherein said medicinal ingredient magnesium sulfate is generally 20%～50% (percentage by weight), is preferably 25%-45% (percentage by weight), is more preferably to adopt 33%-45% (percentage by weight) magnesium sulfate.Lignocaine is then got the treatment effective dose, should be according to feelings to be cured the disease, the patient's that receives treatment age and physiological situation, degree is in a bad way, the course of treatment, factor such as length and medicinal part was determined, preferred 0.1%～4% (percentage by weight) be 1%～3% (percentage by weight) more preferably, is more preferably to adopt 1%～2% (percentage by weight).
The present invention compares its distinguishing feature with the soak method that present hospital often adopts and is:
1 prescription is simple, adopts the compound magnesium sulfate solution soaking, in the condition production of clean environment through the scientific method high temperature sterilize.Selecting high-hydroscopicity napkin, non-woven fabrics, gauze or medical dressing sheet for use is carrier, absorb more complete, the pharmaceutical quantities abundance, drug absorption is more complete, has avoided the first pass effect of endo-medicine liver.
2 antiinflammatory go the swollen onset that relieves the pain fast, Wet-dressing agent 1～10min basic absorption, and strong osmotic, through focus has shortened administration time.The drug action time is long, and only need stick 1-3 time every day, is the desirable medication of chemotherapy, erysipelas, phlebitis and subcutaneous dropsy pain patients.
The Wet-dressing agent of 3 sulfated compound magnesium solutions easy to use adopts low sensitivity high-hydroscopicity napkin, non-woven fabrics, gauze or medical dressing to avoid irritated generation substantially, and the while is pollution clothes not, and is easy to use, guarantees carrying out smoothly of body infusion treatment.
4 used sulfated compound magnesium solution, gauzes are all produced through strict sterilization in the environmental condition of 100,000 grades of cleanings, environmental condition lower seal 10,000 grades of cleanings, and prevented the infection that the bacteria attack affected part is caused through sterilization treatment, guaranteed patient's safe handling.
The present invention further discloses compound magnesium sulfate wet-dressing agent and swelling pain that edema produces occurs and in the application aspect the prevention chemotherapeutic phlebitis in the treatment local subcutaneous tissue.The following compositions that studies have shown that compound magnesium sulfate wet-dressing agent because of intravenous drip chemotherapy, erysipelas medicine, causes that subcutaneous dropsy pain aspect has the obvious synergistic effect in treatment, and clinical effectiveness is satisfied, now is reported as follows.
1, clinical data
1.1 physical data
Year March in March, 2005-2007, select above-mentioned period hospital because of the patient of intravenous drip chemotherapy, erysipelas medicine since the improper liquid that causes in the venous transfusion process of restlessness or PeV puncture position ooze out and exosmose to the subcutaneous patient's of swelling and ache 68 examples, man's 35 examples, women 33 examples, 26～78 years old age.Be divided into observation group's 36 examples at random, matched group 32 examples.Two groups of sexes, age, the state of an illness, Therapeutic Method compare, and difference does not have the significance meaning, has comparability.
1.2 Therapeutic Method
1.2 method
1.2.1 operational approach: matched group 32 examples are used hot towel soak 15～20min then with the painful area that the folk prescription magnesium sulfate dressing preparation is placed on limbs, every day 2-3 time, observe the pain situation.
Observation group's 36 examples are united the compound magnesium sulfate wet-dressing agent of 2% lidocaine hydrochloride with 33% magnesium sulfate, are placed on the painful area soak 1～10min of limbs, every day 2-3 time, observe the pain situation.
1.2.2 evaluation methodology:, pain is divided into 5 grades according to the language description of patient to pain.
0 grade: no pain, subcutaneous tissue swelling is disappeared fully, the distending pain sense disappears, it is normal that sensory perception recovers, activity freely, it is normal that skin elasticity is recovered.
1 grade, mild pain, subcutaneous tissue swelling is disappeared, and it is normal that sensory perception recovers;
2 grades, pain is arranged, can stand, subcutaneous tissue swelling is disappeared substantially.
3 grades, pain, it is painful that the patient feels, and subcutaneous tissue swelling is disappeared not exclusively;
4 grades, sharp ache, the distending pain sense exists, and sensory perception is blunt, and it is poor that skin elasticity is recovered.
5 grades, severe pain is impatient at, treatment; Invalid.
2 results
The 36 routine patient main suits of observation group: soak compound magnesium sulfate wet-dressing agent 1 day, wherein the soak compound magnesium sulfate wet-dressing agent is 5 minutes, and promptly reaching no pain (0 grade) has 28 people; Promptly reached mild pain (1 grade) in 10 minutes 5 people are arranged; Pain was arranged in 10 minutes, can stand (2 grades) 3 people.
Patient main suit in matched group 32 examples: soak folk prescription magnesium sulfate dressing preparation 1 day, soak compound magnesium sulfate wet-dressing agent reached no pain (0 grade) in 1 day 2 people; Mild pain (1 grade) has 3 people; Pain is arranged, can stand (2 grades) 3 people.Pain in various degree appears in most of patient, and the patient feels that painful (3 grades) have 16 people; 6 routine sharp aches (4 grades) chemotherapy that can not hold on wherein, 2 examples are refused to treat because of standing to have an intense pain.
3 discuss
This group result of the test shows, observation group's soak compound magnesium sulfate wet-dressing agent, and reaction can obviously ease the pain.Wherein not having pain or mild pain rate is 91.66%, and 2～4 grades of pain rates of matched group reach 100.0%.Compound magnesium sulfate wet-dressing agent mainly is that lignocaine belongs to the amide-type local anesthetic, can act on nerve, improve the required valve current potential of generation neural impulse, suppress the speed that the action potential depolarization is risen, forfeiture nerve excitability and conductivity, thereby reach analgesic effect.Wherein effective ingredient 33% magnesium sulfate is united the compound magnesium sulfate wet-dressing agent that 2% lidocaine hydrochloride makes and can be seen through skin (general 1-10 minute) rapidly, can play a role at once in swelling place, and have antiinflammatory, promotes the edema Absorption; Can promote partial blood circulation, stimulate damaged tissues regeneration, alleviate limb swelling and pain rapidly.Prompting: the soak compound magnesium sulfate wet-dressing agent can be alleviated subcutaneous swelling and ache, and effect is better than the folk prescription magnesium sulfate dressing preparation.So the soak compound magnesium sulfate wet-dressing agent is being worth of widely use aspect the treatment of chemotherapy, erysipelas, phlebitis and subcutaneous dropsy pain patients.
The specific embodiment
Below by the specific embodiment, foregoing of the present invention is described in further detail, embodiment only is indicative, means that never it limits the scope of the invention by any way.But do not breaking away under the above-mentioned technological thought situation of the present invention, the various replacements of making according to ordinary skill knowledge and habitual means or the modification of change include within the scope of the invention.
Embodiment 1
Under the working condition of 100,000 grades of cleanings, 1. get magnesium sulfate 450g and add an amount of injection dissolving as requested; 2. get appropriate containers in addition lidocaine hydrochloride 10g is added the proper amount of water for injection dissolving as requested, water for injection adds to 1000ml; 3. will be 1., 2. behind the mixing, be the sand rod filtration of 0.80 μ m with the aperture.Wherein magnesium sulfate content and lidocaine hydrochloride content should be up to specification through checking for medicinal liquid; PH value is controlled at 5.5; Medicinal liquid is standby after the assay was approved.To put into container through the gauze of tailoring the slabbing work of sterilization treatment, qualified medicinal liquid soaks 50min to add the check content of dispersion, seal (pack and seal and under the condition of local 10,000 grades of cleanings, to finish) in the high pressure resistant pyritous plastic bag of the sterilization treatment of packing into, put into the sterilization cabinet then adopting 100 ℃ of steam sterilization 30min, promptly can be made into.
Embodiment 2
Under the working condition of 100,000 grades of cleanings, 1. get magnesium sulfate 330g and add an amount of injection dissolving as requested; 2. get appropriate containers in addition lidocaine hydrochloride 20g is added the proper amount of water for injection dissolving as requested, water for injection adds to 1000ml; 3. will be 1., 2. behind the mixing, be the sand rod filtration of 0.80 μ m with the aperture.Wherein magnesium sulfate content and lidocaine hydrochloride content should be up to specification through checking for medicinal liquid; PH value is controlled at 6.5; Medicinal liquid is standby after the assay was approved.To put into container through the gauze of tailoring the slabbing work of sterilization treatment, qualified medicinal liquid soaks 30min to add the check content of dispersion, seal (pack and seal and under the condition of local 10,000 grades of cleanings, to finish) in the high pressure resistant pyritous plastic bag of the sterilization treatment of packing into, put into the sterilization cabinet then adopting 100 ℃ of steam sterilization 45min, promptly can be made into.
Embodiment 3
Under the working condition of 100,000 grades of cleanings, 1. get magnesium sulfate 500g and add an amount of injection dissolving as requested; 2. get appropriate containers in addition lidocaine carbonate 10g is added the proper amount of water for injection dissolving as requested, water for injection adds to 1000ml; 3. will be 1., 2. behind the mixing, filter with the sand rod of aperture 0.80 μ m.Wherein magnesium sulfate content and lidocaine carbonate content should be up to specification through checking for medicinal liquid; PH value is controlled at 5.5; Medicinal liquid is standby after the assay was approved.To put into container through the gauze of tailoring the slabbing work of sterilization treatment, qualified medicinal liquid soaks 60min to add the check content of dispersion, seal (pack and seal and under the condition of local 10,000 grades of cleanings, to finish) in the high pressure resistant pyritous plastic bag of the sterilization treatment of packing into, put into the sterilization cabinet then adopting 100 ℃ of steam sterilization 30min, promptly can be made into.
Embodiment 4
Typical using method and effect introduction:
When (1) using quiet chemotherapeutics of big medicine (as the chemotherapeutics) beginning of chemical stimulation, compound magnesium sulfate wet-dressing agent is moved towards along vein, entirely spread on the distending pain position, drip off, pull out pin 1～2h and stop soak until chemotherapeutics.
(2) use the local hot-wet compress of compound magnesium sulfate wet-dressing agent, entirely spread on the swelling pain position that the edema generation occurs, each 1-30min, every day 1-3 time is till detumescence.Severe swelling pain person, soak sulfated compound Wet-dressing agent can add plastic protective film for plastics, the part of swelling pain is all wrapped up add fomentation, has obtained satisfied curative effect for the local edema pain that causes of exosmosing at the transfusion herb liquid.
(3) prevent chemotherapeutic phlebitis usually, clinical observation 20 routine intravenous chemotherapy are united 2% lidocaine hydrochloride partial soak with 33% magnesium sulfate and are applied the incidence rate that can obviously reduce chemotherapeutic phlebitis and alleviate phlebitic degree and patient's pain.Do not have 1 example in 20 examples phlebitis takes place, thereby alleviate patient's misery greatly, and improve patient's quality of life.
Claims (8)
1. a compound magnesium sulfate wet-dressing agent is characterized in that, it is that 20%-50% magnesium sulfate, 0.1%～4% lignocaine and surplus water for injection and medical carrier are formed by percetage by weight.
2. the described compound magnesium sulfate wet-dressing agent of claim 1, wherein magnesium sulfate is 25%-45%; Lignocaine is 1%～3%.
3. the described compound magnesium sulfate wet-dressing agent of claim 1, wherein magnesium sulfate is 33%-45%; Lignocaine is 1%～2%.
4. each described compound magnesium sulfate wet-dressing agent of claim 1-3, lignocaine wherein is lidocaine hydrochloride or lidocaine carbonate.
5. each described compound magnesium sulfate wet-dressing agent of claim 1-3, medical carrier wherein is high-hydroscopicity napkin, non-woven fabrics, gauze or medical dressing sheet.
6. method for preparing each described compound magnesium sulfate wet-dressing agent of claim 1-3 is characterized in that it is through following step:
(1) 200g～500g magnesium sulfate is made into aqueous solution with the water for injection dissolving, standby;
(2) 1g～40g lignocaine is made into aqueous solution with the water for injection dissolving, standby;
(3) will be 1., 2. behind the mixing, water for injection adds to 1000ml, filters through the sand rod, the control pH value is standby in 5～7 medicinal liquids check magnesium sulfate, the qualified back of lignocaine content;
(4) under the working condition of 10,000 grades of cleanings, will put into container through the medical carrier of sterilization treatment, add the medicinal liquid (3) that is up to the standards and soak 30～60min, pack into and seal through in the high pressure resistant pyritous plastic bag of sterilization treatment;
(5) adopt 100 ℃ of steam sterilization 30～45min, make the compound magnesium sulfate wet-dressing sheet.
7. each described compound magnesium sulfate wet-dressing agent of claim 1-3 application aspect the swelling pain that edema produces occurs in preparation treatment local subcutaneous tissue.
8. the application of each described compound magnesium sulfate wet-dressing agent of claim 1-3 aspect preparation prevention chemotherapeutic phlebitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101517861A CN101366968A (en) | 2008-09-26 | 2008-09-26 | Compound magnesium sulfate wet-dressing agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101517861A CN101366968A (en) | 2008-09-26 | 2008-09-26 | Compound magnesium sulfate wet-dressing agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101366968A true CN101366968A (en) | 2009-02-18 |
Family
ID=40411058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101517861A Pending CN101366968A (en) | 2008-09-26 | 2008-09-26 | Compound magnesium sulfate wet-dressing agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101366968A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552222A (en) * | 2012-01-12 | 2012-07-11 | 朱修桥 | Magnesium sulfate wet application |
| CN102579479A (en) * | 2011-01-12 | 2012-07-18 | 李运智 | Special solution for preventing skin lesion after chemotherapeutic drug exosmosis |
| CN102631697A (en) * | 2012-05-10 | 2012-08-15 | 贾国平 | Preparation and test method of magnesium sulfate dried piece |
| CN103690515A (en) * | 2013-12-09 | 2014-04-02 | 中国人民解放军第四军医大学 | Surface anesthesia membrane for laser therapy and preparation method thereof |
| CN105726582A (en) * | 2016-04-05 | 2016-07-06 | 北京世纪博康医药科技有限公司 | Medicine composition for treating phlebitis and dermatitis |
-
2008
- 2008-09-26 CN CNA2008101517861A patent/CN101366968A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579479A (en) * | 2011-01-12 | 2012-07-18 | 李运智 | Special solution for preventing skin lesion after chemotherapeutic drug exosmosis |
| CN102552222A (en) * | 2012-01-12 | 2012-07-11 | 朱修桥 | Magnesium sulfate wet application |
| CN102552222B (en) * | 2012-01-12 | 2013-07-31 | 朱修桥 | Magnesium sulfate wet application |
| CN102631697A (en) * | 2012-05-10 | 2012-08-15 | 贾国平 | Preparation and test method of magnesium sulfate dried piece |
| CN103690515A (en) * | 2013-12-09 | 2014-04-02 | 中国人民解放军第四军医大学 | Surface anesthesia membrane for laser therapy and preparation method thereof |
| CN105726582A (en) * | 2016-04-05 | 2016-07-06 | 北京世纪博康医药科技有限公司 | Medicine composition for treating phlebitis and dermatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102139033B (en) | Chinese medicinal composition for treating skin wound of pregnant woman after cesarean section | |
| CN103705613A (en) | External-use drug for treating burns and scalds | |
| CN101366968A (en) | Compound magnesium sulfate wet-dressing agent and preparation method thereof | |
| CN102526411B (en) | Chinese medicinal composition for treating surgical wound | |
| CN100540067C (en) | Sterile Magnesium Sulfate Moisture Pack | |
| RU2432146C1 (en) | Method of relieving pain shock severity in burning injury | |
| CN103127168A (en) | Hydropathic compress paste containing magnesium sulfate as well as preparation method and application of paste | |
| RU2530605C2 (en) | Composition for injections, which contains hydroxychloroquine, for local application in treatment of haemorrhoid | |
| CN101401890B (en) | External use medicament capable of effectively treating wound surface infection | |
| CN103610920B (en) | Quick-acting hydrojet of burn and scald and preparation method thereof | |
| CN104383234A (en) | Multi-effect local anesthetic | |
| CN101543555B (en) | Combined medicine for treating burn and scald | |
| CN101028365B (en) | Medicine for treating burn and ambustion and its production | |
| Conard et al. | Delayed recognition of podophyllum toxicity in a patient receiving epidural morphine | |
| CN102058618A (en) | Emla magnesium sulfate wet dressing agent and preparation method thereof | |
| CN113813308A (en) | Medicine for treating burn and scald and preparation method thereof | |
| CN103800488B (en) | A kind of deposited Qizhong medicine for the treatment of the rear limbs swelling pain of fracture | |
| CN104306734B (en) | Treat diabetic gangrene externally applied ointment preparation and preparation method thereof | |
| CN102526382A (en) | Plaster for relieving swelling and pain | |
| CN101695514B (en) | Traditional Chinese medicinal preparation for treating trauma and cicatricial hyperplasia gargalesthesia and preparation method thereof | |
| CN103638095B (en) | A kind of preparation method of dermatosis treating medicine | |
| CN101564443A (en) | Traditional Chinese medicine for treating intravenous injection extravasation stasis and swelling | |
| CN117599148A (en) | Foot-use Chinese and western medicine combination medicine and preparation method thereof | |
| CN103285132B (en) | External preparation for treating skin wound | |
| CN105311391A (en) | Chinese herbal medicine for treating open wound and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090218 |